Regeneron Pharmaceuticals said on Monday it would buy 23andMe out of bankruptcy for $256 million.
The acquisition gives Regeneron the company’s genetic samples and data for millions of individuals.
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions https://t.co/wh3uEsfQH7 pic.twitter.com/1bg9I6tUzi
— New York
Continue reading

Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!